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We report the first seroprevalence study of the occur-
rence of specific antibodies to European bat lyssavirus
type 2 (EBLV-2) in Daubenton’s bats. Bats were captured
from 19 sites across eastern and southern Scotland.
Samples from 198 Daubenton’s bats, 20 Natterer’s bats,
and 6 Pipistrelle’s bats were tested for EBLV-2. Blood sam-
ples (N = 94) were subjected to a modified fluorescent
antibody virus neutralization test to determine antibody
titer. From 0.05% to 3.8% (95% confidence interval) of
Daubenton’s bats were seropositive. Antibodies to EBLV-2
were not detected in the 2 other species tested. Mouth
swabs (N = 218) were obtained, and RNA was extracted
for a reverse transcription–polymerase chain reaction (RT-
PCR). The RT-PCR included pan lyssavirus-primers (N
gene) and internal PCR control primers for ribosomal
RNA. EBLV-2 RNA was not detected in any of the saliva
samples tested, and live virus was not detected in virus
isolation tests.
R
abies is a public health problem in most parts of the
world. In Europe, in addition to classic carnivore-
based rabies virus strains, 2 European bat lyssaviruses
(EBLV-1 and EBLV-2) have been identified (>700 cases)
in several European bat species (1). In 2003, a new bat
virus, West Caucasian bat virus, was reported in Europe
(2). Classical rabies virus is the archetype virus of the
Lyssavirus genus that with 5 other genera make up the
family Rhabdoviridae within the order Mononegavirales.
The Lyssavirus genus is differentiated into 7 genetically
divergent lineages, Rabies virus (genotype 1), Lagos bat
virus (genotype 2), Mokola virus (genotype 3), Duvenhage
virus (genotype 4), EBLV-1 (genotype 5), EBLV-2 (geno-
type 6), and Australian bat lyssavirus (genotype 7). With 1
exception (Mokola virus), all remaining genotypes have
been isolated from bats (3). EBLVs are generally not trans-
missible to terrestrial animals other than bats (4), although
3 cases in humans occurred in an 18-year period, 1 case in
a Stone marten (Martes foina), and 5 cases in sheep (Ovis
aries) (5). However, underreporting occurs throughout
parts of Europe, and in some circumstances rabies is con-
firmed without genetic typing of the virus. This underre-
porting was demonstrated in a confirmed case of rabies
that occurred after a 15-year-old girl was bitten on the fin-
ger by a bat of unknown species in Voroshilovgrad (now
Lugansk), Ukraine, in 1977 (6). A lyssavirus was isolated
from the girl’s brain, but the virus was not genetically
typed (5).
EBLV-2 is the only lyssavirus that has been detected in
the United Kingdom (5). Four cases of infection with this
virus in England have been reported in Daubenton’s bats
(Myotis daubenton’sii): a pregnant female in 1996 in
Sussex (7), a juvenile female in 2002 and an adult male in
2003 in Lancashire (8,9), and a juvenile female in 2004 in
Surrey (10) (Figure 1). In November 2002 in Scotland, the
first human case of rabies (with suspected bat involve-
ment) since 1902 was reported (11) (Figure 1). These sus-
pected cases were all confirmed as EBLV-2 infections by
laboratory diagnosis. Rabies was previously reported in
quarantined animals and in humans with the classical form
of this disease from foreign countries (12).
The exact prevalence of EBLVs in bats in the United
Kingdom is not known. From 1987 to 2004, a total of 4 of
5,030 bats were found to be infected with EBLVs in the
United Kingdom through surveillance programs funded by
the Department for Environment, Food and Rural Affairs.
However, during this period of surveillance, only 99
Daubenton’s bats were submitted for testing. Thus, the
proportion of Daubenton’s bats tested is underrepresented
compared with estimates of Daubenton’s bats in the popu-
lation in the United Kingdom. Nineteen cases of infection
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All (with 1 exception) were in European myotid species:
Daubenton’s bats and Pond bats (M. dasycneme).
However, the latter is not indigenous to the British Isles,
and Pond bat roosts have not been reported anywhere in
the United Kingdom. Similar surveillance strategies have
been used in other European countries (13).
The active surveillance described in this study investi-
gated the prevalence of EBLV-2 in bats across southern
and eastern Scotland by detecting antibodies to EBLV-2 in
blood by using a modified fluorescent antibody virus neu-
tralization (mFAVN) test and assessing oral swabs for the
presence of lyssavirus RNA. The mFAVN test for EBLV-2
and polymerase chain reaction assays were developed as
research techniques and used as surveillance tools after the
death of a bat conservationist in 2002 (11). Previous stud-
ies have successfully demonstrated this approach to detect
EBLV-1 in bat colonies from Spain (14–16). The emer-
gence of new virulent bat lyssaviruses in Europe (2)
emphasizes the need for continual appraisal and surveil-
lance for the presence of lyssaviruses in European bats.
Methods
Sample Collection
From April to October 2003, a total of 229 bats were
caught on 22 nights at 19 locations in Scotland (Figure 2).
Each bat was assessed for health, sex, age, and reproduc-
tive status. Features examined in each bat for signs of poor
health included unusual posture, matted fur, discharges
from the orifices, thin appearance, excessively injured
wings (rips, tears, and punctures), and excessive parasite
burden. In addition, both weight and forearm measure-
ments were taken, and bats that were unusually light for
their skeletal size were examined more closely. Behavioral
signs also noted included loss of coordination, seizures,
and persistent aggression. Bats were required to fly at the
end of sampling. An inability to fly after feeding, rehydra-
tion, and warming indicated debilitation. Any unusual
observations were recorded. 
A 2.9-mm, uniquely numbered bat ring (Mammal
Society, London, UK) was fitted for individual recogni-
tion. Mouth swabs (saliva) were taken from each bat with
either a dry sterile swab or a combination of dry and wet
sterile swabs. These were stored individually in 500-µL
sterile transport buffer (L15 medium [Sigma, St. Louis,
MO, USA] containing 2 mmol L-glutamine, 50 µg/mL of
penicillin, 2 µg/mL of streptomycin, 2 µg/mL of nystatin,
and 2% fetal calf serum).
Blood (up to 100 µL) was taken by puncture from the
antebrachial or uropatagial veins (in some bats after appli-
cation of a local anesthetic cream [Lignocaine gel,
Dunlop’s Vet Supplies, Dumfries, UK]) by using a 26-
gauge needle and then collected by using 10- to 50-µL
heparinized glass capillary tubes (Statspin, Norwood, MA,
USA). Aproprietary antibleeding product (Hemablock vet-
erinary wound powder, Dunlop’s Vet Supplies) was then
applied to each puncture site. The capillary tubes were then
emptied into a sterile screw-topped tube. To increase blood
volume obtained, 50 bats were attached by elastic bands to
a thin cork board that was placed on a heated surface
(≈43°C) to ensure vasodilatation of the peripheral veins.
All samples were refrigerated and stored at ≈4°C until test-
ing (1–5 days later). Capturing, handling, ringing, and
sampling of bats were done under guidelines approved by
the Home Office (UK Project Licenses PPL 60/3122 and
PPL 30/1948).
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Figure 1. Distribution of Daubenton’s bats in the United Kingdom
and Ireland showing 5 cases of infection with European Bat
lyssavirus type 2 (EBLV-2). Open circles are sites where
Daubenton's bats were observed away from their roosts, and the
closed circles are roosts of Daubenton’s bats (summer and win-
ter). The 5 numbered gray circles are sequential sites where
EBLV-2-positive cases were found. Reprinted with permission of
The Bat Conservation Trust (London, United Kingdom) from
Distribution of Bats in Britain and Ireland 1980–1999.From 25% to 35% of sampled bats were recaptured
bats. Recapturing occurred within days of original sam-
pling and also during a 1-year period from the date of ini-
tial sampling. This finding suggests that the sampling
procedure was not harmful to bats. Ethical constraints in
the United Kingdom restrict the resampling of wild bats
within 3 months of capture. For this reason, additional
sampling opportunities were limited. 
Sample Analysis
mFAVN Test
A fluorescent antibody test (a virus neutralization
assay) is routinely used to measure levels of antibodies to
rabies virus in sera from vaccinated animals by using
rabies virus strain CVS. The mFAVN test used in this study
was based on the routine test but used an EBLV-2 virus
(RV628, a Daubenton’s bat isolate from the United
Kingdom in 1996, EBLV-2a GenBank U89478/
AY721613) (7), instead of rabies virus. A conjugate
(Centacor, Fujirebio Diagnostics Inc., Malvern, PA, USA)
was used at a dilution of 1:40. Samples were analyzed in
duplicate because of their small volume and serially dilut-
ed using a 3-fold series (representing reciprocal titers of 9,
27, 81, and 243–19,683). No significant difference was
observed in a comparison of duplicate versus quadrupli-
cate tests on rabies-vaccinated pet sera (Veterinary
Laboratories Agency, Weybridge, UK, unpub. data).
This assay was monitored for reproducibility with pos-
itive controls (anti-rabies virus sera [Office International
des Epizooties, Agence Française de Sécurité Sanitaire des
Aliments, Nancy, France] and a pooled anti-EBLV-2 [inac-
tivated RV628] serum from rabbits) and negative controls
(normal pooled dog and normal pooled rabbit sera, Harlan,
Loughborough, UK). A positive serum sample from an
EBLV-2–infected bat was not available for full validation
of this test. 
The mFAVN test is a quantitative procedure requiring a
threshold to separate positive from negative results. To
eliminate false-positive results, studies in Spain (16) used
a reciprocal titer of 27 as a cutoff for EBLV-1, while oth-
ers (14) used a threshold titer of 9. We used a reciprocal
titer ≥27 as a positive cutoff level; samples with lower
titers were considered negative. When applied to pooled
samples, this threshold may underestimate the actual num-
ber of EBLV–2-positive bats; with a cutoff value of 1:27,
weakly positive samples might have been overlooked.
Further studies during consecutive years in a longitudinal
study would provide confirmatory data indicating the
prevalence of EBLV-2 in Scotland.
Where necessary, samples were combined to give the
minimum volume (50 µL) needed for the test. Blood was
pooled only across 1 species at any given site and with
samples of a similar volume, such that plasma from an
individual bat contributed equally to the pooled sample. As
a result of pooling and being unable to determine the num-
ber of bats that were antibody positive or negative in a
pooled sample, the 95% confidence intervals (CIs) were
broader than if no pooling had taken place.
Reverse Transcriptase–Polymerase 
Chain Reaction (RT-PCR)
The presence of virus can be determined directly by
using an RT-PCR (17) that detects the RNA of all
lyssavirus genotypes (including EBLV-1 and EBLV-2).
The sensitivity of this RT-PCR and a hemi-nested PCR is
of the order of 0.1 and 10-3 50% tissue culture infectious
doses of rabies virus (18). Similar values have been
obtained for EBLVs (Veterinary Laboratories Agency,
Weybridge, UK, unpub. data). The interpretation of PCR
results assumes that each swab contained saliva or cells
from the oral cavity. To determine this, a separate riboso-
mal RNA (rRNA) PCR (18) was conducted to detect host
RESEARCH
574 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 4, April 2005
Figure 2. Bat sampling locations in southern and eastern Scotland.
The circles indicate both the location (number) and an estimate of
the number (size) of bats sampled. oral rRNA. The result for the lyssavirus RNA PCR was
reported as unknown if rRNA was not detected. In con-
trast, if the swab was positive for rRNA, the lyssavirus
PCR result was reported as either positive or negative.
Methods used in this study were as previously described
(17,18), with 250 µL of transport medium for the initial
RNA extraction. 
Isolation of Virus
Seronegative bats were tested by a rabies tissue culture
infection test (RTCIT) only, while seropositive bats were
tested by both the RTCIT and the mouse inoculation test
(MIT) as previously described (19,20). The RTCIT tech-
nique was conducted by using 100 µLof transport medium
per well in duplicate wells on 96-well plates. For the MIT,
4-week-old outbred CD1 mice (Charles River, Margate,
UK) were injected intracranially with 40-µL samples that
were antibody positive. Two mice were used per sample.
The MIT was conducted according to the Home Office
guidelines (UK Project License PPL 70/4867), and mice
were monitored for 41 days before being humanely killed. 
Statistical Analysis
Prevalence was calculated for sites at which we did not
expect to find seropositive bats. This prevalence includes
bats chosen from all Scottish sites, and a separate preva-
lence was calculated for site 1 (Figure 2). We anticipated
that site 1 would be a location where EBLV-2–positive bats
might be found because this site was the geographic region
in which the suspected human exposure to EBLV-2 was
reported (Figure 2) (11). Confidence limits were calculat-
ed as follows. An initial estimate for the proportion of bats
that were seropositive for EBLV-2 was calculated with a
maximum likelihood function 
where p is the unknown probability of being seropositive,
xi is the number of positive sample of pools of size i, and
yi is the number of negative pools of size i. The maximum
likelihood estimate (p^) was then used to generate the
approximate 95% confidence limits by assuming 2 [ln L
(p^) – ln L (p)] is approximately χ2 distributed. All calcu-
lations were programmed in R (21). 
Results
Blood was collected from 230 bats: 198 (85%)
Daubenton’s bats, 24 Natterer’s bats (Myotis natterii), and
8 Pipistrelle’s bats (Pipistrellus species). Of these, blood
from 224 bats was subjected to the mFAVN test. Fifty-five
(24.5%) blood samples were tested individually; the rest
were combined into pools containing 2–9 samples, with
most containing 3 samples. The distribution of these
samples across different sites is shown in the Table. The
effects of pooling samples on the performance of the
mFAVN test have not been fully investigated, but no evi-
dence suggests that a pool containing multiple seropositive
bat samples shows test behavior quantitatively different
from a pool containing 1 seropositive bat sample.
Calculations of prevalence were performed only for
blood samples (or pools) in which a successful positive or
negative result was obtained. Positive samples were
obtained in 4 pools (containing serum from 9, 2, 2, and 3
bats) and 2 single samples, and were exclusively from
Daubenton’s bats caught at 2 sites (Figure 3). This finding
represents 6–18 bats since a minimum of 1 bat from each
pool may have been antibody-positive. Determining
whether the high value of the reciprocal titer (243) pro-
duced by 1 pool of 3 bats (site 15) (Figure 2) represents >1
seropositive bat in this pool was not possible. All
Natterer’s bats (5 pools) and Pipistrelle’s bats (1 pool)
sampled were negative. The prevalence of EBLV-2 for the
Natterer’s and Pipistrelle’s bats tested was not significant
because of the limited number of each species sampled. 
Host rRNA was detected in 218 (65%) of the samples,
indicating that saliva, cells, or both were present on the
swab. In the remaining 35%, RNAwas absent or below the
limit of detection. No difference was detected in the abili-
ty to detect RNAwhen wet and dry swabs were compared.
None of the results of the first-round or heminested PCRs
with any of the samples were positive for lyssaviruses.
These data suggest that none of the bats tested were active-
ly excreting virus. 
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bats swabs) and MIT (antibody-positive bat swabs only).
All RTCIT samples were negative and at day 41 after
injection, clinical signs of infection had not developed in
any mouse. These data indicate that live virus was not
detectable in the oral swab samples.
If the bats tested in this study (with the exception of
those at site 1) were a truly random selection of
Daubenton’s bats across Scotland, the likely prevalence
(95% CI ) of bats testing seropositive for EBLV-2 would
be 0.05%–3.80%. The 95% CI for the prevalence of
EBLV-2–seropositive bats at site 1 was 2.9%–16.3%.
Discussion
The development of techniques to detect lyssavirus
infection and previous exposure is fundamental to under-
standing both the risks to humans posed by EBLVs and in
studying virus epidemiology. Results from Spanish
(14–16) and North American (22) studies suggest that the
relationship between lyssaviruses isolated from bats, the
role of the immune system, and excretion of virus in the
saliva are complex. Seroprevalence levels of EBLV-1 in
individual and mixed-species bat colonies in Spain during
9 years of sampling increased from 3% in 1 year to 59%
the next year and subsequently decreased to 10% by the
end of the study (16). Other investigators in the United
States have reported a high seroprevalence for rabies virus
(15%–20% per colony, range <5%–34%) in big brown bats
(Eptesicus fuscus) (22).
Bats in the United States and Spain may coexist with
rabies virus and EBLV-1, respectively; some bats are
healthy and breed successfully for a number of years
(14–16,22). If this case also is true of EBLV-2, the virus
would be difficult to detect directly, but a long-term obser-
vation of antibody-positive bats would be expected. 
Our study shows that the seroprevalence of EBLV-2 is
generally low (<4%) and that active virus excretion is
below the limit of detection used. If this prevalence of
EBLV-2 was distributed evenly throughout Scotland, sam-
ples from large numbers of bats would be needed to refine
this estimate. The effect of using the same detection
threshold in the mFAVN test for both single and pooled
samples may result in an underestimate of the number of
antibody-positive bats.
Antibodies to EBLV-2 in Daubenton’s bats were found
at only 2 of 19 sampled sites in Scotland. Whether the
lower prevalence rates in Scotland will persist and are a
function of either the bat or the virus being at the norther-
ly edge of its range, or as suggested by a Spanish study
(16), will change considerably over time, is not known.
EBLV-2 was not detected on oral swabs of the
Daubenton’s bats. These data suggest that virus was not
excreted by the bats at the time of sampling and that an
abortive peripheral infection with sterilizing immunity to
EBLV-2 may have occurred. Thus, our findings are differ-
ent from those in Spain and North America in which a low
proportion of bats showed measurable levels of EBLV-1 or
rabies virus in saliva associated with detectable antibody
titers (14–16,22). These data also imply that differences in
virulence exist between EBLV-2, EBLV-1, and rabies
virus. An experimental study of EBLVs in ferrets demon-
strated that EBLV-2 was rapidly cleared with the onset of
a substantial neutralizing antibody titer (23). 
Our understanding of the biology of bats and their inter-
action with EBLVs is limited, and it affects our ability to
fully interpret prevalence rates. The principal tool used to
determine the rates of disease prevalence, the mFAVN test,
directly measures the EBLV-2 antigen-specific neutraliz-
ing antibody response. Changes affecting the immune state
of the bat may have implications in our ability to detect an
EBLV-2 infection. The gravid state and other physiologic
stress scenarios in bats may change their immune response
with respect to lyssaviruses (24). Unfortunately, bats, in
particular myotid bats, are most accessible in their hiber-
nacula, their maternity roosts (when most are pregnant or
lactating), or at swarming sites (of which few are known
and include mainly male bats). 
Despite such problems, we have detected antibodies to
EBLV-2 in the blood of Daubenton’s bats, albeit at low
levels and low rates of prevalence. Data were insufficient
to determine the geographic extent of the study sites, but
both sites with seropositive bats are in well-watered low-
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Figure 3. Antibody titers to European bat lyssavirus type 2 (EBLV-
2) in bat sera from Scotland. An EBLV-2-specific modified fluores-
cent antibody virus neutralization (mFAVN) test was used to
determine the level of circulating antibody in Daubenton’s bats
from 19 sites in Scotland. The test uses a 3-fold dilution series (9,
27, 81, 243, etc.) and the positive/negative cutoff is a titer (recip-
rocal dilution) of 27. Circles on the graph represent either single
serum samples or pools of sera (88 for Daubenton’s bats, 5 for
Natterer’s bats, and 1 from Pipistrelle’s bats). All titers  27 are
Daubenton’s bats from 2 sites (5 from site 1 and 1 from site 15).
No data were available for sites 2, 17, and 19. land landscapes likely to support a high density of
Daubenton’s bats. Areas of higher bat density would nor-
mally be considered more likely to support endemic dis-
ease. The number of Daubenton’s bats in the United
Kingdom has been estimated at 150,000 (25), with
≈40,000 in Scotland (Scottish Natural Heritage, unpub.
data), and colony sizes range from 10 to 200 with an aver-
age of 20 individuals (Bat Conservation Trust and Central
Science Laboratory, unpub. data). The number of
Daubenton’s bats found across the United Kingdom has
also been increasing by 4.4% per year since 1997 (Bat
Conservation Trust, unpub. data). These data on the preva-
lence of EBLV-2 in Daubenton’s bats, coupled with the
first isolation of EBLV-2 in the United Kingdom in 1996
and the distribution of cases in the United Kingdom
(Figure 1) (7–10), suggest that this zoonosis may be
emerging in the United Kingdom and requires continuing
surveillance and management (5).
Rabies virus can elicit a measurable antibody response
after exposure, but not all exposures are lethal; some lead
to an abortive infection (26). Although virus replication in
the central nervous system was not measured in our study,
virus replication can occur in this location without rabies
developing in the host, mainly because of the susceptibili-
ty of the host to virus of low pathogenicity. Our data imply
that bats in Scotland do not recover from infection after
exposure to EBLV-2. Moreover, Daubenton’s bats exhibit
a low level of susceptibility to the virus and are subse-
quently developing an immune response after contact with
EBLV-2 viral antigens. 
In future studies, following up this research and succes-
sively resampling specific sites to establish disease pro-
files for ringed bats within this population will be
important. To this end, blood samples of sufficient volume
to permit individual tests must be obtained from seroposi-
tive bats over time at sites where positive cases have
occurred (Figure 2) and at randomly selected locations.
The available evidence suggests that the prevalence of
EBLV-2 in Daubenton’s bats in Scotland is low and may be
sporadic (27). These bats may roost less frequently in
human dwellings than some other species; thus, the risk of
human contact with infectious bats is low. Public health
policies have been developed in the United Kingdom to fur-
ther reduce exposure and potential for disease in those con-
sidered at risk. These measures include education, rabies
vaccination for those working with bats, and postexposure
treatment for people bitten or scratched by any bat species.
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